Literature DB >> 21613873

Perfusion MRI using dynamic-susceptibility contrast MRI: quantification issues in patient studies.

Fernando Calamante1.   

Abstract

OBJECTIVES: Measurement of perfusion accurately, noninvasively, and with good spatial resolution offers the chance to characterize abnormal tissue in many clinical conditions. Dynamic-susceptibility contrast (DSC) MRI, also known as bolus-tracking MRI, is a dynamic MRI method to measure perfusion and other related hemodynamic parameters. This review article describes the principles involved in perfusion quantification using DSC-MRI as well as discusses the main issues affecting its quantification in patient studies.
CONCLUSIONS: It is shown that DSC-MRI is a very powerful technique that provides important information regarding cerebral hemodynamics. The relatively high contrast-to-noise ratio, fast acquisition, and wealth of information available have made DSC-MRI the most commonly used MRI technique for the rapid assessment of the brain hemodynamics in clinical investigations. While very important advances have been achieved in the last 2 decades, there are still some remaining limitations that users should be aware of to avoid misinterpretation of the findings and to make the most of the invaluable information provided by perfusion MRI.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21613873     DOI: 10.1097/RMR.0b013e31821e53f5

Source DB:  PubMed          Journal:  Top Magn Reson Imaging        ISSN: 0899-3459


  14 in total

1.  Feasibility of MR perfusion-weighted imaging by use of a time-spatial labeling inversion pulse.

Authors:  Yoshiyuki Ishimori; Hiraku Kawamura; Masahiko Monma
Journal:  Radiol Phys Technol       Date:  2013-05-24

2.  ASFNR recommendations for clinical performance of MR dynamic susceptibility contrast perfusion imaging of the brain.

Authors:  K Welker; J Boxerman; A Kalnin; T Kaufmann; M Shiroishi; M Wintermark
Journal:  AJNR Am J Neuroradiol       Date:  2015-04-23       Impact factor: 3.825

Review 3.  Neuroimaging of Peptide-based Vaccine Therapy in Pediatric Brain Tumors: Initial Experience.

Authors:  Andre D Furtado; Rafael Ceschin; Stefan Blüml; Gary Mason; Regina I Jakacki; Hideho Okada; Ian F Pollack; Ashok Panigrahy
Journal:  Neuroimaging Clin N Am       Date:  2017-02       Impact factor: 2.264

4.  The effects of propofol on cerebral perfusion MRI in children.

Authors:  Julie H Harreld; Kathleen J Helton; Roland N Kaddoum; Wilburn E Reddick; Yimei Li; John O Glass; Rakhee Sansgiri; Qing Ji; Tianshu Feng; Mary Edna Parish; Amar Gajjar; Zoltan Patay
Journal:  Neuroradiology       Date:  2013-05-15       Impact factor: 2.804

5.  Pseudo-extravasation rate constant of dynamic susceptibility contrast-MRI determined from pharmacokinetic first principles.

Authors:  Xin Li; Csanad G Varallyay; Seymur Gahramanov; Rongwei Fu; William D Rooney; Edward A Neuwelt
Journal:  NMR Biomed       Date:  2017-09-08       Impact factor: 4.044

6.  A novel approach to measure local cerebral haematocrit using MRI.

Authors:  Fernando Calamante; André Ahlgren; Matthias J P van Osch; Linda Knutsson
Journal:  J Cereb Blood Flow Metab       Date:  2015-09-30       Impact factor: 6.200

Review 7.  Advances in translational imaging of the microcirculation.

Authors:  Marie Guerraty; Akanksha Bhargava; Janaka Senarathna; Asher A Mendelson; Arvind P Pathak
Journal:  Microcirculation       Date:  2021-03-13       Impact factor: 2.679

Review 8.  Characterization of the Tumor Microenvironment and Tumor-Stroma Interaction by Non-invasive Preclinical Imaging.

Authors:  Nirilanto Ramamonjisoa; Ellen Ackerstaff
Journal:  Front Oncol       Date:  2017-01-31       Impact factor: 6.244

9.  Radiotherapy planning using MRI.

Authors:  Maria A Schmidt; Geoffrey S Payne
Journal:  Phys Med Biol       Date:  2015-10-28       Impact factor: 3.609

10.  Practical dynamic contrast enhanced MRI in small animal models of cancer: data acquisition, data analysis, and interpretation.

Authors:  Stephanie L Barnes; Jennifer G Whisenant; Mary E Loveless; Thomas E Yankeelov
Journal:  Pharmaceutics       Date:  2012       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.